CWA Asset Management Group LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 11.9% in ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Adding CKD to the label for Jardiance (empagliflozin ... helping it to post a near-50% increase in sales for the drug last year to almost $4.4 billion. Boehringer and Lilly's drug is already ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ...

FDA insistence that companies must undertake long-term cardiovascular outcomes trials is transforming the type 2 diabetes market, and Boehringer Ingelheim and Lilly’s Jardiance pill now looks ...

In 2022, empagliflozin (Jardiance) was approved for a broader ... SUMMIT participants were around age 65 years on average, over 50% women, and about 30% non-white. Baseline EF was around 61% ...

Ares weapon names Verseau Completes $50 Million Financing to Develop Macrophage Checkpoint Modulators Boehringer/Eli Lilly's Jardiance new indication ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

50 Cent can’t help himself. The “In da Club” rapper, 49, went after Jay-Z on Instagram Monday when the Roc Nation founder, 55, went to the “Mufasa: The Lion King” premiere after being ...